Back to search

Peptide record

TPDB43059

37-mer peptide Anticancer standard
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB43059
37-mer peptide
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 37-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
Sequence
TKEQKEQIAKATGLTTKQVRNWYVQLNASIKVCMCSC
Physicochemical Analysis
C180H302N52O55S4
DHFP
K
4202.93
9.56
6
2
13
+4
8.01
-0.405
73.78
Mammalian: 7.2 hour Yeast: >20 hour E.coli: >10 hour
7115
169.29
16
Residue Composition
number
3
A
1
R
2
N
0
D
3
C
2
E
4
Q
1
G
0
H
2
I
2
L
5
K
1
M
0
F
0
P
2
S
4
T
1
W
1
Y
3
V
Amino Acid Distribution
A: 3 R: 1 N: 2 D: 0 C: 3 E: 2 Q: 4 G: 1 H: 0 I: 2 L: 2 K: 5 M: 1 F: 0 P: 0 S: 2 T: 4 W: 1 Y: 1 V: 3
Chemical Descriptors
37
C180H302N52O55S4
4202.93
9.56
+4
8.01
-0.405
Free
L
Linear
Free
Antimicrobial
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 76.4 ± 0.6015 µM
Anticancer
76.4

Target

Liver Cancer
SNU-449
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 33.65 ± 1.09 µM
Anticancer
33.65

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023
Evidence 3 Activity

Activity

IC50
IC50 = 27.45 ± 1.5085 µM
Anticancer
27.45

Target

Ovarian cancer
SK-OV-3
Ovary

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023